Related Experiment Video
Updated: May 4, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Tracing the path of non-industry-driven medicine development for rare diseases through regulatory interactions at the
Noa Rosenberg1, Carla E M Hollak2, V A Haverhoek3
1Medicines for Society (Medicijn voor de Maatschappij), Platform at Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands; Department of Endocrinology and Metabolism, Amsterdam UMC, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Expertise Center for Inborn Errors of Metabolism, MetabERN, University of Amsterdam, Amsterdam, The Netherlands; Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
Abstract:
Non-industry organizations, including academia, charities, and public institutes, increasingly contribute to rare disease medicine development. In this study, we reviewed orphan designations (ODs) granted between 2000 and 2022, comparing non-industry and industry outcomes. Of 2734 ODs, 183 (6.7%) originated from non-industry organizations. Protocol assistance was obtained for 33% of non-industry and 35% of industry ODs, with distinct peaks for non-industry ODs in 2015 and 2017 linked to European grant calls promoting regulatory engagement. Only six non-industry ODs led to marketing authorization, all post transfer to industry. Our findings indicate lower transition rates yet partial long-term convergence, highlighting the value of targeted grants and regulatory support.
More Related Videos
06:30Generation of a Simplified Three-Dimensional Skin-on-a-chip Model in a Micromachined Microfluidic Platform
Published on: May 17, 2021
09:33Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India
Published on: December 23, 2022
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Preclinical Development: Overview
Drug Control Governance: Regulatory Bodies and Their Impact